ArticleImmunity & ageing : I & A2026
Impaired function of Vγ9Vδ2 T cells in frail elderly.
Article in Immunity & ageing : I & A, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Repair and regeneration across the lifespan: an ontogenetic perspective.Frontiers in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFrailty, a geriatric syndrome of multisystem physiological decline, elevates vulnerability to adverse health outcomes and involves immunosenescence. While T cell dysfunction is implicated, alterations in the major circulating γδ T cell subset, Vγ9Vδ2 T cells, remain largely unexplored in frailty. This study aims to systematically investigate the transcriptomic, phenotypic, and functional alterations of Vγ9Vδ2 T cells in frail older adults to elucidate their potential role in frailty-associated immune dysregulation.
resultsWe isolated Vγ9Vδ2 T cells from 12 frail and 12 non-frail older adults aged 60–100 years, performing Smart RNA-Seq2 transcriptomic profiling on subsets of 7 participants per group. Protein expression measured by flow cytometry and function assessed by cytokine assays were subsequently validated in distinct subsets of 5 participants per group. Transcriptomic analysis revealed over 700 DEGs between groups, enriched in immune pathways. Validation showed Vγ9Vδ2 T cells from frail individuals had reduced activation potential, with CD69 expression approximately one-third lower, and markers of exhaustion, including PD-1 and LAG-3 expression approximately two-fold higher. Functionally, these cells exhibited severely impaired cytotoxicity, shown by reduced IFN-γ, FasL, Granzymes A/B, and Perforin production.
conclusionTo our knowledge, our study is among the first to report a distinct exhaustion-like phenotype in Vγ9Vδ2 T cells from frail older adults, characterized by reduced activation, high PD-1, and impaired cyto-toxicity. These findings suggest that Vγ9Vδ2 T-cell dysfunction may represent a component of immune dysregulation in frailty, suggesting a potential link to the increased immune vulnerability observed in these individuals. Targeting Vγ9Vδ2 T cell function thus represents a novel potential therapeutic strategy to mitigate frailty-associated immune deficits and improve health in older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.